Abbott’s Absorb GT1 stent system secures CE Mark for treatment of CAD

19 May 2015 (Last Updated May 19th, 2015 18:30)

Abbott has received CE Mark for its Absorb GlideTrack (GT1) catheter for the treatment of patients with coronary artery disease (CAD).

Abbott has received CE Mark for its Absorb GlideTrack (GT1) catheter for the treatment of patients with coronary artery disease (CAD).

An upgraded version of Abbott's Absorb stent system, the Absorb GT1 combines the world's first fully dissolving stent with a next-generation delivery catheter to simplify access for doctors and treat diseased vessels in CAD patients.

Abbott Vascular Medical Affairs chief medical officer Charles Simonton said: "Coronary artery disease is the most common disease in developed countries, and the new Absorb GT1 catheter delivery system may improve the ability of doctors to treat more people with CAD by opening up coronary blockages in hard-to-reach areas with this novel, fully dissolving stent."

"An upgraded version of Abbott's Absorb stent system, the Absorb GT1 combines the world's first fully dissolving stent with a next-generation delivery catheter to simplify access for doctors and treat diseased vessels in CAD patients."

Contilia Heart and Vascular Centre (Essen, Germany) director Christoph Kurt Naber said: "Dissolving stents are the next logical step in the treatment of patients with coronary artery disease as these stents completely dissolve after opening up clogged arteries and restoring blood flow.

"With the prevalence of CAD around the world, this therapy has the potential to improve the health of many people."

Absorb functions like a metallic stent by opening a blocked artery in the heart and restoring blood flow, and dissolves over time unlike a metallic stent that cages the vessel, leaving behind a treated vessel free of a permanent implant.

In 2014, Abbott announced positive one-year clinical results from ABSORB II, the world's first prospective, randomised, controlled trial comparing the safety and effectiveness of the fully dissolving Absorb to Abbott's market-leading, metallic Xience family of drug eluting stents.

Featuring 501 people with CAD, the trial was conducted primarily in Europe, and data will be presented during EuroPCR, which started on 19 May in Paris, France.

Absorb is available in more than 70 countries worldwide,and the company recently completed its submission for regulatory approval in Japan, and plans to submit reports, including data from pivotal trials, for regulatory approvals in the US and China in the future.

Absorb is currently an investigational device in the US and is not approved for commercial use in the country.